Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $87.00 price target on the stock.
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer [Yahoo! Finance]
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly